Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bristol-Myers Squibb (BMY) Receives a Buy from Barclays

Tipranks - Tipranks - Wed Apr 22, 4:10AM CDT

In a report released today, Emily Field from Barclays maintained a Buy rating on Bristol-Myers Squibb, with a price target of $75.00.

Claim 30% Off TipRanks

Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Cytokinetics. According to TipRanks, Field has an average return of 1.4% and a 42.94% success rate on recommended stocks.

In addition to Barclays, Bristol-Myers Squibb also received a Buy from Bank of America Securities’s Jason Gerberry in a report issued on April 9. However, on April 13, Wells Fargo assigned a Hold rating to Bristol-Myers Squibb (NYSE: BMY).

See the top stocks recommended by analysts >>

Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.5 billion and a net profit of $1.09 billion. In comparison, last year the company earned a revenue of $12.34 billion and had a net profit of $72 million

Read More on BMY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).